BPC-157 Research: VEGFR2 Signalling and Cell Biology Pathway Studies

BPC-157 Research: VEGFR2 Signalling and Cell Biology Pathway Studies

BPC-157 is a research compound studied in cell-based assay formats for its VEGFR2 receptor pharmacology, FAK/paxillin signalling, and NO synthase pathway modulation. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.

Receptor Pharmacology and Mechanism of Action

BPC-157 demonstrates complex receptor pharmacology through multiple cellular targets. Competitive radioligand binding assays reveal interactions with VEGFR2 (vascular endothelial growth factor receptor 2), showing measurable binding affinity in the micromolar range. The compound exhibits selective receptor engagement patterns that distinguish it from endogenous VEGF ligands in cell membrane preparations.

The peptide's mechanism of action involves modulation of focal adhesion kinase (FAK) and paxillin signalling cascades. In vitro phosphorylation assays demonstrate concentration-dependent effects on FAK autophosphorylation at Tyr397, with downstream consequences for paxillin phosphorylation status. These signalling events occur within 15-30 minutes of compound exposure in cultured endothelial cell models.

VEGFR2 Pathway Activation Studies

Primary Signalling Events

VEGFR2 receptor activation by BPC-157 initiates distinct intracellular signalling patterns compared to canonical VEGF stimulation. Flow cytometry-based receptor internalisation assays show modified kinetics of receptor trafficking, with sustained membrane expression observed over extended incubation periods. This altered trafficking pattern correlates with prolonged downstream signalling activity in multiple endothelial cell lines.

Enzyme-linked immunosorbent assays (ELISA) measuring phospho-VEGFR2 levels reveal peak activation occurring 10-15 minutes post-treatment, with signal duration extending beyond 2 hours in serum-starved cell cultures. The compound demonstrates dose-response relationships with EC50 values varying across different cell model systems.

Secondary Messenger Cascades

BPC-157 treatment activates phospholipase C gamma (PLCγ) pathways downstream of VEGFR2 engagement. Calcium mobilisation assays using fluorescent indicators show characteristic biphasic calcium responses in endothelial cell monolayers. Initial rapid calcium release from intracellular stores is followed by sustained calcium entry through membrane channels.

Protein kinase B (Akt) phosphorylation occurs through PI3K-dependent mechanisms, as confirmed by specific kinase inhibitor studies. Western blot analysis reveals phospho-Akt (Ser473) elevation persisting for 4-6 hours following BPC-157 exposure in multiple cell model systems.

FAK/Paxillin Signalling Network Analysis

Adhesion Complex Formation

BPC-157 modulates focal adhesion dynamics through FAK-dependent mechanisms. Immunofluorescence microscopy reveals altered focal adhesion morphology and distribution patterns in treated cell cultures. Quantitative analysis shows increased focal adhesion size and density at cell-substrate interfaces within 1-2 hours of compound exposure.

Paxillin phosphorylation at multiple tyrosine residues (Tyr31, Tyr118, Tyr181) occurs downstream of FAK activation. Co-immunoprecipitation experiments demonstrate enhanced FAK-paxillin complex formation in BPC-157-treated samples compared to vehicle controls.

Cytoskeletal Reorganisation

Cell-based assays monitoring actin cytoskeleton dynamics show BPC-157-induced stress fiber formation and membrane ruffle development. Time-lapse microscopy reveals enhanced cell spreading and membrane protrusion activity in multiple adherent cell lines. These morphological changes correlate temporally with FAK/paxillin phosphorylation events.

Nitric Oxide Synthase Pathway Modulation

BPC-157 influences endothelial nitric oxide synthase (eNOS) activity through multiple regulatory mechanisms. Enzyme activity assays demonstrate concentration-dependent effects on NO production in endothelial cell lysates. The compound affects both eNOS phosphorylation status and substrate availability for enzymatic activity.

Griess reagent-based assays measuring nitrite accumulation show biphasic dose-response curves in cultured endothelial cells. Lower concentrations enhance NO production, while higher concentrations show diminished activity, suggesting complex regulatory mechanisms involving multiple cellular targets.

Real-time PCR analysis reveals transcriptional effects on NOS3 gene expression, with peak mRNA levels occurring 4-6 hours post-treatment. These transcriptional changes correlate with sustained NO production capacity in extended culture experiments.

Research Summary

BPC-157 demonstrates multifaceted receptor pharmacology involving VEGFR2 activation, FAK/paxillin signalling modulation, and NO synthase pathway regulation. In vitro studies reveal concentration-dependent effects on cellular signalling cascades, with distinct kinetic profiles for different pathway components. The compound's complex mechanism of action involves both immediate post-receptor signalling events and longer-term transcriptional modifications, making it a valuable research tool for investigating endothelial cell biology and vascular signalling networks in controlled laboratory environments.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML